Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Source:http://linkedlifedata.com/resource/pubmed/id/18260618

J. Med. Chem. 2008 Mar 13 51 5 1145-9

Download in:

View as

Triples

General Info

PMID
18260618